Includes drugs indicated for different types of arthritis as well as the form and strength the medication is available in.
Researchers described the prevalence of self-reported frailty among patients with rheumatic musculoskeletal diseases and its associated factors.
Orphengesic Forte for the symptomatic relief of mild to moderate pain of acute musculoskeletal disorders is now available.
The FDA has approved the supplemental Abbreviated New Drug Application (sANDA) for Orphengesic Forte.
From 2005 to 2016, skeletal muscle relaxant (SMR) use increased in the United States.
EULAR developed provisional recommendations for the management of rheumatic and musculoskeletal diseases during the COVID-19 pandemic.